What is the recommended protocol for NAD (Nicotinamide Adenine Dinucleotide) injections in patients, including those with a history of addiction or substance use?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

NAD Injection Protocol

There is no established, evidence-based protocol for NAD injections in clinical practice, as current research is limited to oral supplementation studies and one small pilot study using IV infusions for substance use disorder—not standardized injections. 1, 2, 3

Current Evidence Limitations

The available literature does not support injectable NAD as a standard medical intervention:

  • Oral supplementation is the only well-studied route: Research has focused exclusively on oral NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide) with dosing ranging from 250-2000 mg daily for 4-12 weeks. 1, 2

  • The single IV study used prolonged infusions, not injections: One pilot study administered NAD via IV infusion (not injection) in 50 patients with substance use disorder, but provided no standardized dosing protocol, infusion duration, or concentration details. 3

  • No safety data exists for injectable NAD: Unlike established injectable medications with FDA-approved protocols (such as naloxone 2 mg IM/IN for opioid overdose 4 or ferumoxytol 1020 mg IV over 15 minutes for iron deficiency 5), NAD injections lack pharmacokinetic studies, safety profiles, or dosing guidelines. 1, 2

Critical Clinical Considerations

If NAD injections are being considered for substance use disorder specifically, the evidence is insufficient to recommend this approach:

  • The pilot study showing reduced cravings, anxiety, and depression used IV infusions (not injections) with unspecified dosing, and lacked placebo controls, randomization, or long-term follow-up. 3

  • Standard addiction treatment should take priority: Patients with substance use disorder require evidence-based interventions including naltrexone (50 mg daily oral or 380 mg monthly injection), buprenorphine maintenance, behavioral therapy, and psychosocial support. 6, 7

  • For patients with active addiction history, any injectable therapy carries risks of misuse, diversion, and triggering relapse behaviors. 6, 8

Recommended Alternative Approach

Oral NAD+ precursor supplementation is the only route with established safety data:

  • Nicotinamide riboside: 250-1000 mg daily 2
  • Nicotinamide mononucleotide: 250-500 mg daily 2
  • Duration: 4-12 weeks with monitoring 1, 2
  • Common side effects: muscle pain, headache, fatigue, sleep disturbance (all mild and self-limited) 1

Injectable NAD protocols promoted in wellness clinics or alternative medicine settings lack scientific validation and should not be used in medical practice without rigorous clinical trial data establishing safety, efficacy, pharmacokinetics, and appropriate dosing. 1, 2

References

Research

Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.

American journal of physiology. Endocrinology and metabolism, 2024

Research

Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions.

The journals of gerontology. Series A, Biological sciences and medical sciences, 2023

Guideline

Naloxone Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pain Management for Patients with Substance Use Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Prescribing Adderall in Patients with Methamphetamine Addiction History

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.